Treats erectile dysfunction. ANDA 205988, held by Macleods Pharms. Vardenafil Hydrochloride.
As of Nov 16, 2026, ANDA 205988 (Vardenafil Hydrochloride), held by Macleods Pharms, was first approved by FDA on Mar 10, 2020, with 1 approved supplement and 0 published complete response letters.
Vardenafil orally disintegrating tablet is indicated for the treatment of erectile dysfunction.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Mar 10, 2020 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Vardenafil Hydrochloride10MG · tablet, orally disintegrating;oral | Vardenafil Hydrochloride | Rx |
| Oct 30, 2023 | Supplement 7Labeling · Standard review | Approved | None posted |
| Mar 10, 2020 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters